New options in the treatment of depression;Neue wege in der depressionsbehandlung

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 11, 2007, Pages 641-652

  Frieling, Helge ^a   Hillemacher, T ^a   Demling, J H ^a   Kornhuber, J ^a   Bleich, S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antidepressants; Depression; Drug discovery

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CASOPITANT; CITALOPRAM; DESIPRAMINE; DOPAMINE; FLUOXETINE; GLUCOCORTICOID; GLUTAMIC ACID; KETAMINE; MELATONIN; MIRTAZAPINE; MOCLOBEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; NORADRENALIN; PAROXETINE; PHENELZINE; REBOXETINE; RILUZOLE; SEROTONIN; SEROTONIN AGONIST; TIANEPTINE; TRANYLCYPROMINE; UNINDEXED DRUG; VASOPRESSIN; VESTIPITANT;

CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; HUMAN; NEUROTRANSMISSION; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER;

EID: 36749001094     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959181     Document Type: Review

References (126)

1. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097-1106
2. Paykel ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005; 15: 411-423
3. Dohmen C, Garlip G, Sitzer M, Siebler M, Malevani J, Kessler KR, Huff W. Post-Stroke-Depression. Algorithmus fur ein standardisiertes diagnostisches Vorgehen in der klinischen Routine. Fortschr Neurol Psychiatr 2006; 74: 257-262
4. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151
5. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, Vaugeois JM, Nomikos GG, Greengard P. Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science 2006; 311: 77-80
6. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10-21
7. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006; 7: 139-147
8. Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 1996; 10: 16-27
9. Kreiss DS, Lucki I. Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse 1997; 25: 107-116
10. Bosker FJ, Westerink BH, Cremers TI, Gerrits M, Hart MG van der, Kuipers SD, Pompe D van der, Horst GJ ter, Boer JA den, Korf J. Future antidepressants: what is in the pipeline and what is missing? CNS Drugs 2004; 18: 705-732
11. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252
12. Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol 2005; 25: 79-84
13. Amsterdam JD, Brunswick DJ, Gibertini M. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial. J Psychiatr Res 2004; 38: 259-265
14. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 243-249
15. Heinrich T, Bottcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Amsterdam C Van. Synthesis and structure - activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem 2004; 47: 4684-4692
16. Roberts C, Hagan JJ, Bartoszyk GD, Kew JN. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol 2005; 517: 59-63
17. Storosum JG, Elferink AJ, Zwieten BJ van, Block BW van den, Huyser J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004; 37: 32-36
18. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005; 2: 590-611
19. Simiand J, Keane PE, Guitard J, Langlois X, Gonalons N, Martin P, Bianchetti A, Le Fur G, Soubrie P. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. Eur J Pharmacol 1992; 219: 193-201
20. ADIS International R&D profile. SR 58611A: SR 58 611. Drugs R D 2003; 4: 380-382
21. Halaris AE, Belendiuk KT, Freedman DX. Antidepressant drugs affect dopamine uptake. Biochem Pharmacol 1975; 24: 1896-1897
22. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977; 53: 309-314
23. DeBattista C, Lembke A. Update on augmentation of antidepressant response in resistant depression. Curr Psychiatry Rep 2005; 7: 435-440
24. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401
25. Gross G, Xin X, Gastpar M. Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991; 30: 1159-1166
26. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-151
27. Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J, Klajblova H, Kulist'ak P, Ressner P, Svatova J, Urbanek K, Veliskova J. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406
28. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65
29. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566
30. Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307-314
31. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798
32. Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004; 20: 131-138
33. Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, Bogetto F. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 2002; 70: 313-317
34. Cassano GB, Jori MC. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17: 27-32
35. Amore M, Jori MC. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16: 317-324
36. Schmauss M, Messer T. Dysthymie. Fortschr Neurol Psychiatr 2005; 73: 415-424
37. Mucci A, Nolfe G, Maj M. Levosulpiride: a review of its clinical use in psychiatry. Pharmacol Res 1995; 31: 95-101
38. Amsterdam JD, Brunswick DJ, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1333-1338
39. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003; 461: 99-104
40. FDA. First depression patch approved. FDA Consum 2006; 40: 4
41. Wessel K, Szelenyi I. Selegiline - an overview of its role in the treatment of Parkinson's disease. Clin Investig 1992; 70: 459-462
42. Benedictis E. 20 mg transdermal selegiline daily may be effective and well tolerated in adults with major depression. Evid Based Ment Health 2003; 6: 44
43. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64: 208-214
44. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159: 1869-1875
45. Frieling H, Bleich S. Tranylcypromine: New perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci 2006; 256: 268-273
46. Yildiz-Yesiloglu A, Ankerst DP. Review of (1)H magnetic resonance spectroscopy findings in major depressive disorder: A meta-analysis. Psychiatry Res 2006; 147: 1-25
47. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003; 60: 618-626
48. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441
49. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265: 1380-1386
50. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864
51. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589-590
52. Zarate CA Jr, Singh JB, Quiroz JA, DeJesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-155
53. Kos T, Legutko B, Danysz W, Samoriski G, Popik P. Enhancement of Antidepressant-Like Effects but Not Brain-Derived Neurotrophic Factor mRNA Expression by the Novel N-Methyl-D-aspartate Receptor Antagonist Neramexane in Mice. J Pharmacol Exp Ther 2006; 318: 1128-1136
54. Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Rev Bras Psiquiatr 2005; 27: 243-248
55. Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res 1998; 116: 153-170
56. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487
57. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001; 40: 1028-1033
58. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska E. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002; 440: 27-35
59. Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM. Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther 2003; 307: 297-305
60. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20: 8-21
61. Thome J, Bleich S. Molekularbiologische Grundlagen antidepressiver Therapie. In: Demling J (Hrsg). Therapieresistente Depressionen. Bremen; London; Boston: UNI-MED Verlag AG, 2004: 80-87
62. Danysz W. LY-544 344. Eli Lilly. IDrugs 2005; 8: 755-762
63. Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004; 125: 191-201
64. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate CA Jr, Manji HK. The Anticonvulsants Lamotrigine, Riluzole, and Valproate Differentially Regulate AMPA Receptor Membrane Localization: Relationship to Clinical Effects in Mood Disorders. Neuropsychopharmacology 2006; doi: 10.1038/sj.npp.1301178
65. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-174
66. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, DeJesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-432
67. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 2004; 161: 2132
68. Nowak G, Partyka A, Palucha A, Szewczyk B, Wieronska JM, Dybala M, Metz M, Librowski T, Froestl W, Papp M, Pilc A. Antidepressant-like activity of CGP 36 742 and CGP 51 176, selective GABA(B) receptor antagonists, in rodents. Br J Pharmacol 2006; 149: 581-590
69. Ong J, Kerr DI. Clinical potential of receptor modulators. CNS Drug Rev 2005; 11: 317-334
70. Pilc A, Nowak G. GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) 2005; 41: 755-766
71. Vieta E, Manuel GJ, Martinez-Aran A, Comes M, Verger K, Masramon X, Sanchez-Moreno J, Colom F. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67: 473-477
72. Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006; 67: 66-71
73. Ebert D, Kaschka W. Humorale Aspekte des Schlafentzuges. Fortschr Neurol Psychiatr 1995; 63: 441-450
74. Melatonin. Monograph. Altern Med Rev 2005; 10: 326-336
75. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in Psychiatric Disorders: A Review on the Melatonin Involvement in Psychiatry. Frontiers in Neuroendocrinology 2001; 22: 18-32
76. Beck-Friis J, Kjellman BF, Aperia B, Unden F, Rosen D von, Ljunggren JG, Wetterberg L. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand 1985; 71: 319-330
77. Brown R, Kocsis JH, Caroff S, Amsterdam J, Winokur A, Stokes PE, Frazer A. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry 1985; 142: 811-816
78. Boer JA den, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 2006; 21 Suppl 1: S21-S24
79. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93-100
80. Tuma J, Strubbe JH, Mocaer E, Koolhaas JM. Anxiolytic-like action of the antidepressant agomelatine (S 20 098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol 2005; 15: 545-555
81. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E. Antidepressant action of agomelatine (S 20 098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 908-916
82. Loiseau F, Le Bihan C, Hamon M, Thiebot MH. Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats. Psychopharmacology (Berl) 2005; 182: 24-32
83. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20 098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126-133
84. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28: 694-703
85. Loo H, Dalery J, Macher JP, Payen A. Etude pilote comparant en aveugle l'effet therapeutique de deux doses d'agomelatine - agoniste des recepteurs de la melatonine et antagoniste des recepteurs 5HT2c - chez 30 patients. Encephale 2002; 28: 356-362
86. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247
87. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280
88. Papp M, Litwa E, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006; 17: 9-18
89. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19: 1057-1065
90. Prestele S, Aldenhoff J, Reiff J. Die HPA-Achse als mogliches Bindeglied zwischen Depression, Diabetes mellitus und kognitiven Störungen. Fortschr Neurol Psychiatr 2003; 71: 24-36
91. Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995; 38: 797-802
92. Sharma R, Hedeker D, Pandey G, Janicak P, Davis J. A longitudinal study of plasma cortisol and depressive symptomatology by random regression analysis. Biol Psychiatry 1992; 31: 304-314
93. Szyf M, Weaver ICG, Champagne FA, Diorio J, Meaney MJ. Maternal programming of steroid receptor expression and phenotype through DNA methylation in the rat. Frontiers in Neuroendocrinology 2005; 26: 139-162
94. Kunzel HE, Ising M, Zobel AW, Nickel T, Ackl N, Sonntag A, Holsboer F, Uhr M. Treatment with a CRH-1-receptor antagonist (R121919) does not affect weight or plasma leptin concentration in patients with major depression. Journal of Psychiatric Research 2005; 39: 173-177
95. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research 2000; 34: 171-181
96. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression. Biol Psychiatry 2006; 60: 1343-1349
97. Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J Neuroendocrinol 2006; 18: 629-631
98. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry 2004; 61: 1235-1244
99. Serradeil-Le Gal C, Derick S, Brossard G, Manning M, Simiand J, Gaillard R, Griebel G, Guillon G. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 2003; 6: 199-206
100. Cirillo R, Gillio TE, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, Golzio L, Marinelli P, Thomas RJ, Chevillard C, Laurent F, Portet K, Barberis C, Chollet A. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2- pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther 2003; 306: 253-261
101. Griebel G, Stemmelin J, Gal CS, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 2005; 11: 1549-1559
102. Overstreet DH, Hlavka J, Feighner JP, Nicolau G, Freed JS. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology (Berl) 2004; 175: 303-309
103. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26: 911-944
104. Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005; 19: 275-293
105. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485-490
106. Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 2002; 63 Suppl 11: 25-29
107. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biological Psychiatry 2006; 59: 216-223
108. Rupniak NM. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can J Physiol Pharmacol 2002; 80: 489-494
109. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrie P. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001; 299: 449-458
110. Kalra SP, Kalra PS. NPY - an endearing journey in search of a neurochemical on/off switch for appetite, sex and reproduction. Peptides 2004; 25: 465-471
111. Jimenez-Vasquez PA, Diaz-Cabiale Z, Caberlotto L, Bellido I, Overstreet D, Fuxe K, Mathe AA. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur Neuropsychopharmacol 2007; 17: 298-308
112. Karlsson RM, Holmes A, Heilig M, Crawley JN. Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Pharmacol Biochem Behav 2005; 80: 427-436
113. Husum H, Mikkelsen JD, Hogg S, Mathe AA, Mark A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000; 39: 1463-1473
114. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-525
115. Tsankova NM, Kumar A, Nestler EJ. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci 2004; 24: 5603-5610
116. Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT. Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 2004; 127: 51-59
117. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annual Review of Medicine 2006; 57: 553-574
118. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J for the RIO-North America Study Group. Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial. JAMA 2006; 295: 761-775
119. Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E. High activity of acid sphingomyelinase in major depression. J Neural Transm 2005; 112: 1583-1590
120. Kornhuber J, Herr B, Thome J, Riederer P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 1995; 46: 131-137
121. Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 1993; 163: 129-131
122. Akunne HC, Zoski KT, Whetzel SZ, Cordon JJ, Brandon RM, Roman F, Pugsley TA. Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001; 41: 138-149
123. Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004; 37 Suppl 3: S214-S220
124. Bermack JE, Debonnel G. Effects of OPC-14 523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors. J Psychopharmacol 2007; 21: 85-92
125. Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136-151
126. Linden M. Leitlinien und die Psychologie medizinischer Entscheidungsprozesse bei der Behandlung depressiver Erkrankungen. Fortschr Neurol Psychiatr 2005; 73: 249-258